GPBAR1 and metabolic disease: In spite of the promising aforementioned results, the only published human study in which a TGR5 agonist was administered to diabetic patients yielded somewhat disappointing results given that glucose levels were strikingly increased and not reduced as expected.90 Further research is needed to determine whether TGR5‐based therapies would be a viable approach to metabolic disease and NAFLD.